A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Temsirolimus (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Etoposide phosphate; Hydrocortisone; Methotrexate
Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

02 Jul 2020 Status changed from recruiting to completed.
31 May 2020 Results (n= 16) assessing safety profile of temsirolimus in combination with etoposide and cyclophosphamide in high-risk pediatric patients with r/r ALL, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
07 Feb 2020 Planned End Date changed from 1 Dec 2019 to 31 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com